GRM4 and Parkinson disease: In fact, positive allosteric modulators (PAMs) of mGlu4 show promising results in pre-clinical and clinical trials as potential therapeutic agents to reverse motor dysfunction in Parkinson’s disease (PD) (reviewed in Charvin, 2018; Hopkins et al., 2009), but can increase impulsivity in rats (Isherwood, 2017).